Home/Pipeline/Teliso-V (telisotuzumab vedotin)

Teliso-V (telisotuzumab vedotin)

Non-Small Cell Lung Cancer (c-Met+)

Phase 3Active, not recruitingNCT04928846

Key Facts

Indication
Non-Small Cell Lung Cancer (c-Met+)
Phase
Phase 3
Status
Active, not recruiting
Company

About AbbVie

AbbVie's mission is to discover and deliver transformative medicines that solve serious health issues. Its landmark achievement was building the world's top-selling drug, Humira, into a franchise while successfully navigating its patent expiry through a robust pipeline and strategic acquisitions like Allergan. The company's strategy hinges on sustained leadership in immunology, accelerated growth in oncology and neuroscience, and financial discipline to fuel high R&D investment and shareholder returns.

View full company profile

Other Non-Small Cell Lung Cancer (c-Met+) Drugs

DrugCompanyPhase
AL2846Shanghai Allist PharmaceuticalsPhase III